|
- Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral . . .
In this study, LTV prophylaxis was associated with a decreased total cost of care for HR CMV patients through day+180 Specifically, reductions in CMV-related readmissions, exposure to CMV-directed antiviral agents, and outpatient visits in the first 100 days after HCT were observed
- Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral . . .
Highlights • Letermovir prevents csCMV in allogenic HCT pts at high and standard-risk for CMV • Total cost of care was compared for letermovir prophylaxis versus preemptive therapy • For high-risk pts, letermovir decreases total cost of care through day+180 • For standard-risk pts, letermovir reduces inpatient cost of care through
- Transplantation and Cellular Therapy
Preemptive therapy (PET) historically has been the primary strategy to reduce early-onset cytomegalovirus (CMV) reactivation after allogeneic hematopoietic cell transplan-tation (HCT) but is associated with antiviral-associated toxicities and increases in health-care resource utilization and cost
- Letermovir Prophylaxis Versus Pre-Emptive Therapy for Cytomegalovirus . . .
We performed a single-center observational retrospective study to evaluate the efficacy of primary Letermovir prophylaxis for CMV infection among high-risk patients (R+) receiving HSCT from serological negative donor (D-)
- Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus . . .
We summarized and analyzed real-world effectiveness of letermovir primary prophylaxis (PP) for cytomegalovirus (CMV) reactivation, clinically significant CMV infection, CMV disease, and mortality among adult allogeneic hematopoietic cell transplant recipients
- (PDF) Impact of letermovir primary Cytomegalovirus (CMV) prophylaxis on . . .
Background: Letermovir, a novel antiviral, has largely supplanted more traditional preemptive antiviral therapy (PET) for cytomegalovirus (CMV) prophylaxis in allogeneic hematopoietic stem cell
- Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus . . .
Objective: In a retrospective single-centre observational study we evaluated the use of letermovir for prophylaxis or pre-emptive treatment of cytomegalovirus (CMV) infection in seropositive paediatric HCT recipients receiving the compound outside of clinical trials
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell . . .
We found that letermovir prophylaxis to prevent clinically significant CMV infection in CMV-seropositive patients beginning a median of 9 days after hematopoietic-cell transplantation and
|
|
|